Posted by Michael Wonder on 02 Nov 2021
Incyte announces acceptance of NDA for parsaclisib for three types of relapsed or refractory non-Hodgkin lymphomas
1 November 2021 - Priority review granted to NDA for relapsed or refractory marginal zone lymphoma and mantle cell lymphoma.
Incyte today announced that the U.S. FDA has accepted its new drug application for parsaclisib, an investigational novel potent, highly selective, next generation oral inhibitor of phosphatidylinositol 3-kinase delta, for the treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma.
